miércoles, 1 de junio de 2016

Caridad por precios en industria farmacéutica.



Looking for another reason to dislike drug companies? Good news: Some companies systematically use charitable giving as a way to raise their drug prices with minimal public awareness. 

Bloomberg’s Benjamin Elgin and Robert Langreth reported on a number of cases in which drug companies seem to be using charities as a means to milk U.S. taxpayers for all they’re worth. 

Drug companies donate to charities that help patients who are unable to afford the insurance co-payments on expensive drugs. 

The drug companies donate to the co-pay charities so that Americans can afford the out-of-pocket costs of staying on extremely expensive drugs, while the taxpayer-funded Medicare program shoulders the largest part of the total cost.(...) 

 The seven largest co-pay charities in the country received $1.1 billion in total contributions from drug companies in 2014. 

While the law strictly forbids drug companies from giving direct help to Medicare patients, there is no law forbidding them from donating to co-pay charities, which themselves directly help Medicare patients. 

Former Turing Pharmaceuticals CEO Martin Shkreli is reportedly one of many to take advantage of the system. When Turing purchased the drug Daraprim last year, Shkreli immediately raised the drug’s price by more than 5,000 percent. 

Ver:

Precio: El mayor de todos los incrementos...Daraprim (Turing) / Marcia Angell* (II)


Turing then turned around and donated more than a million dollars to co-pay charity Patient Services Inc to ensure that all of its patients would continue to be able to afford their out-of-pocket costs and Turing could gouge Medicare for the majority of the price hike. 

Notable Names 

The authors specifically mentioned the following as companies that have made significant donations to co-pay charities: 

  • Valeant Pharmaceuticals Intl Inc 
  • Jazz Pharmaceuticals plc – Ordinary Shares
  • Novartis AG (ADR)
  • Mallinckrodt PLC -owned Questcor Pharmaceuticals 

Bloomberg concludes that the current co-pay charity donation system has likely played a large role in the explosion in drug prices in recent years.

Ver también: 

TURING´s Ceo, Martin Shkrli, arrestado / Daraprim...“Schadenfreude*.”

Citario/El dijo que...: Gaby Castellanos* El mensaje no es "overimpreessions"





Lo digo cada vez que puedo: 
el volver loca a la gente con el mismo mensaje no hara que te hagan caso ( a menos que hagas propaganda). 
En publicidad, sorry, no funciona. 
No vas a llenar/vender mas entradas porque repitas un mensaje, no te haras famoso porque pongas mas veces tu foto en Instagram, no te creeran guapo/a porque mas te vean, no, sorry. 
La conviccion por repeticion se llama adoctrinamiento y no Publicidad, y mucho menos Marketing. Cuando la creatividad y sin duda, la estrategia es buena con enviar un impacto es suficiente para vender todo lo que tengas que vender, o para simplemente, ser recordado. Si lo necesitas hacer mil veces, querido amigo/a, es que lo estas haciendo MU MAL. Ojo, puede que tengas que hacer retargeting, pero no repeticion. Pero si tu mensaje no llego, no llegara jamas. Sorry.

Ver:

Gaby Castellanos: 7 mandamientos de las redes sociales.


Las grandes creatividades, las grandes estrategias no necesitan de overimpressions, ni de dar por culo al consumidor ni mucho menos aburrirlos, no, para eso ya estan los politicos y asi les va. Pero bueno, siempre habra un visitador medico, testigo de alguna religion o algun vendedor de algun producto nutricional diciendo que asi se hizo millonario, o teniendo followers en Instagram. Ya sabeis...hay de todo en la viña del señor! 
Y si de señor y todo, esta es #LaVida2.0 y yo os quiero 3huevos! Completos y sin ser un coñazo/ladilla/aburriemiento!

 A Gaby la "conocí" en Caracas  en 2010 (aun era "vivible") por algo que publicó"El Nacional".

Citario/El dijo que...: Gaby Castellanos y la oxitocina.


Al regresar a España, después de mis clases, le seguí la pista. Estuve presente en algunas de sus presentaciones, siempre brillantes/rompedoras. Buenos ejercicios para mi "asertividad".
Por eso estuvo (entró y comentó en una ocasión, agradeciendo), está y...estará en PHARMACOSERÍAS

Ver también:

"El social media ha muerto": Gaby Castellanos / El paradigma del ROI y las redes sociales... 

 (*) Gaby Castellanos

martes, 31 de mayo de 2016

Dejar de fumar...con Champix (Pfizer) también es malo...


EMA lifts  warning on  Pfizer's smoking cessation drug Champix 

Pfizer on Monday said that the European Medicines Agency lifted a warning on the smoking cessation therapy Champix (varenicline), regarding an increased risk of neuropsychiatric adverse events associated with the drug, known as Chantix in the US. 
The decision was based on data from the EAGLES post-marketing trial, which did not identify an increased risk of neuropsychiatric side effects linked to the therapy. Rory O'Connor, Pfizer's chief medical officer, remarked that "the new safety and efficacy information in the European label further supports the importance of Champix as a treatment option for healthcare providers and for those who are trying to quit smoking.

 The EAGLES trial was jointly conducted by Pfizer and GlaxoSmithKline at the behest of and in consultation with the FDA and the EMA. In the trial, the results of which were published in The Lancet last month, did not show a significant increase in the incidence of the composite primary safety endpoint of serious neuropsychiatric adverse events with Chantix or Zyban compared to placebo and nicotine patch. The FDA stated that it is "reviewing the findings of this study and substantial supporting documentation from the clinical trial, along with additional published medical literature, as we continue to evaluate this issue. 

Both, the EMA and FDA required Pfizer in 2009 to update the label of Champix to reflect that the therapy had been linked to "serious mental health events, including changes in behaviour, depressed mood, hostility, and suicidal thoughts.





Ver: 
CHANTIX: Y pensar que para PFIZER 150 suicidios no es nada...Solo "expected adverse events".

Meanwhile, a spokeswoman for GlaxoSmithKline, whose anti-smoking treatment Zyban was also required by the EMA to include a label warning against suicidal ideation, noted that it is unclear whether the agency is lifting the warning from the drug's label.(Ver)

Ver: Todo sobre Chantix en PHARMACOSERÍAS

Hoy...Día Mundial sin Tabaco

Fuimos "pioneros" de esta campaña en nuestra iniciativa "corporativa": Mividasinti...

domingo, 29 de mayo de 2016

Sponsorismos "a la sidra": Bebiendo (?) ayudarás....



Sidra frente al cáncer.
 Bebiendo (?) ayudarás....

Con cada botella de ‪#‎sidraselección‬ que consumas en toda España, estarás contribuyendo a financiar proyectos de investigación frente al cáncer.

Ver

sábado, 28 de mayo de 2016

Terapias de los sentidos: Alcoholic spirits


After leaving Lenox Hill Churchill retreated to the Bahamas, from where he reports on 8 January 1932 that "I arrived here physically very weak but with considerable mental energy; then all of a sudden I felt a great deal of nervous reaction and lassitude." He could not concentrate, had recurring pain in his side, difficulty sleeping without sleeping pills, "and from time to time have had some depression of spirit." His impatient agents wanted him to resume his American lecture tour by 15 January, but Churchill knew that was impossible. On 3 January he cabled (Otto) Pickhardt: "am convinced unfit begin lecturing before February one...kindly cable your advice." And Pickhardt heartily concurred, to Churchill's great relief. 

The doctor even granted Churchill medical authorization to purchase and consume alcohol--then illegal in Prohibition America: 

"the post accident convalescence of the Hon. Winston S. Churchill necessitates the use of alcoholic spirits especially at meal times. The Quantity is naturally indefinite..."



viernes, 27 de mayo de 2016

Ratón de biblioteca: "El herbario de Gutemberg" / Raul Guerra Garrido

 

"El primer individuo 
que tomó parte de una planta 
para curarse a si mismo 
tuvo bastante coraje"
James Joyce



 El herbario de Gutenberg”, de Raúl Guerra Garrido, Juan Esteva y Javier Puerto (Turner, 2013, 405 págs). Un obra sobre la “Farmacia y las Letras”, ese es su subtítulo, que puede ser leída como un ensayo terapéutico, una novela o una historia de la Farmacia. 

Según ha explicado Raúl Guerra, el título responde a la tradición de herbarios entre los farmacéuticos y que en este caso las hojas de papel, también vegetales, recogen la cosecha producida en la literatura desde la aparición de la imprenta, parafraseando el célebre ensayo de Marshall McLuhan en “La Galaxia Gutenberg”. 

Lo que este libro nos ofrece es una historia de la Farmacia a través de la literatura universal. 
Tres autores para tres épocas. 

Javier Puerto, catedrático de Historia de la Farmacia de la Universidad Complutense de Madrid y doble académico de las Reales de Farmacia y de la Historia, aborda las obras hispanas desde el baja Edad Media hasta la Crisis del 1898. Su análisis del laboratorio de la alcahueta Celestina es sencillamente magistral. 

Raúl Guerra Garrido, el más reconocido de los farmacéuticos escritores actuales, premio Nadal 1976 y premio Nacional de las Letras Españolas 2006, se ocupa de las referencias a la farmacia en la literatura española del siglo XX y lo que va de siglo XXI. De entre los autores que trata destaca su aproximación a Joan Perucho y su “Botánica oculta o el falso Paracelso” (1986) y a Antonio Gamoneda y su “Libro de los venenos” (1995). 

Juan Esteva de Sagrera, catedrático de Historia de la Farmacia de la Universidad de Barcelona y decano de su Facultad de Farmacia, se ocupa de las obras con farmacia de la literatura universal de todas la épocas. 
Desde su punto de vista, “la farmacia es una extraordinaria y memorable novela que no tiene parangón ni desperdicio y que toca todas las teclas: naturalismo, realismo mágico, dadaísmo y novela negra”. (Ver)


Visitadores médicos en la selva / Pharmaceutical sales reps in the wild.

Join us as we journey to the edge of civilisation where pharmasuiticus rep can be seen in its natural habitat. In order to prevent the extinction of pharma sales entirely... 

Only a few dying remnants of this species now remain. The E4P team have managed to capture the last of this species and are urgently recommending immediate action in order to revitalise the remaining population.

Ver:Sales Reps in the Wild: An Interesting Way to Promote a Sales Force Effectiveness Conference

Thank you also to our intrepid camera crew at www.stantonmedia.com for their courage in coming into such close contact with these dangerous animals.

jueves, 26 de mayo de 2016

Carl Djerassi o Ferdinand Peeters...Quién es el "padre" de la anticoncepción?


Contraceptive pill



Ver

 
Carl Djerassi 

On October 15, 1951, in a small laboratory in Mexico City, one of the key episodes in 20th century social history occurred: the first synthesis of a steroid oral contraceptive-an event that triggered the development of the Pill. Carl Djerassi has been honored worldwide for that accomplishment, which ultimately changed the life of women and the nature of human reproduction in ways that were not then foreseeable. (...)
 This Man's Pill presents a forcefully revisionist account of the early history of the Pill, debunking many of the journalistic and romantic accounts of its scientific origin. Djerassi does not shrink from exploring why we have no Pill for men or why Japan only approved the Pill in 1999 (together with Viagra). Emphasizing that development of the Pill occurred during the post-War period of technological euphoria, he believes that it could not be repeated in today's climate. Would the sexual revolution of the 1960s or the impending separation of sex ("in bed") and fertilization ("under the microscope") still have happened? Djerassi also credits the Pill with radically altering his life, allowing him to become one of the few American chemists to have a second career, that of a novelist and playwright.

Ver también:

Ratón de biblioteca: La píldora, los chimpances pigmeos y el caballo de Degás / Carl Djerassi



Ver


Ferdinand Peeters 

The first birth control pill produced in the United States in 1957 was riddled with side effects and it wasn’t until 1961, when Flemish obstetrician and gynecologist Ferdinand Peeters developed an improved version, that the pill could be widely used by women. 
The Belgian doctor’s pill was the first combined oral contraception introduced outside the US that had ‘acceptable’ side effects and used on a global scale. 

Belgium was strictly Catholic at the time of the pill’s creation, forcing Peeters, who was a conservative Catholic himself, to keep quiet about his experiment to avoid falling foul of Belgian law and religious prohibition on hormonal contraception. Peeters never patented his pill, which would likely have earned him a fortune, and instead it was sold to a German pharmaceutical company and marketed as Anovlar.

Pharma 2015 : Risers & Fallers / Ganadores y perdedores










Ver (descargar)

Click sobre imagen para ampliar 

Within traditional big pharma’s sphere, it is hard to believe that Eli Lilly was the biggest riser two years in a row, but the returns do not lie. From January 2014 through to the end of 2015 the Indianapolis-based group rose an incredible two thirds, with the one-year gains of 2015 amounting to 22%. Lilly was particularly bedevilled by the patent cliff of 2011 and 2012, losing Zyprexa and Cymbalta along the way, and thus had to fight its way back from a low base. 
The progress of Trulicity and Cyramza, along with the promise of baricitinib, ixekizumab and the great mystery, its Alzheimer’s disease project solanezumab, are helping to drive Lilly along. 

Bristol-Myers Squibb’s rise is not as surprising, as its cancer immunotherapy Opdivo is now the poster child for innovation in the pharma sector. 

Sanofi, on the other hand, rebounded well in 2015 following a tumultuous 2014. Selecting a new chief executive, signing some licensing deals and declaring itself ready for more dealmaking seems to have brought the French group back into investors’ favour. 

Big pharma fallers were led by AbbVie – which had been among the top risers in 2014 as it tried to acquire Shire – along with Novartis and Merck & Co

In spite of being in some of the sector’s most popular therapy areas, hepatitis C, immunology and oncology, AbbVie had a hard go of 2015 on the public exchanges. A desperate-looking takeout of Pharmacyclics and fears about Humira biosimilars have to be weighing heavy on AbbVie

Novartis’s position atop pharma sales rankings did little to prevent it from having a bad year, as its Alcon ophthalmology business struggled while its heart failure drug Entresto failed to meet launch expectations. Generic competition for its top-seller, Gleevec, emerged when Sun Pharma announced that it had launched its version in early February 2016, and this also served as a factor in Novartis’s troubles. 

Merck & Co’s presence on the top fallers list is more surprising, given that it too has a leading immuno-oncology agent – but looming generic competition for Zetia and Vytorin, along with a steep loss in revenue for its European Remicade business, cannot be helping.